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Left ventricular end-systolic pressure-volume analysis
was employed to assess the inotropic effect of the phos-
phodiesteraseinhibitor enoximone(formerlyMDL-17,043)
in nine patients with severe heart failure (New York
Heart Association class IV symptoms, mean ejection
fraction =0.22). Left ventricular pressure-volume loops
were constructed using high fidelity left ventricular pres-
sure measured with micromanometer-tipped catheters
and simultaneous left ventricular volume obtained by
gated blood pool imaging. Afterload was reduced with
the vasodilator nitroprusside to generate the baseline left
ventricular end-systolic pressure-volume relation, a rel-
atively load-independent measure of contractile func-
tion.
The intravenous administration of enoximone (mean
dose 75 mg) shifted the end-systolic pressure-volumepoint
upward and leftward from the baseline pressure-volume
A new class of intravenous and oral agents has recently
become available for the treatment of congestive heart fail-
ure (1-4). These agents, which include amrinone, milrinone
and enoximone (formerly MDL-17,043), improve cardiac
function by inhibiting phosphodiesterase F-III (5). Although
both inotropic and vasodilator effects of these drugs have
been documented in vitro, the inotropic effect has been more
difficult to demonstrate in patients with heart failure, in part
because of associated changes in left ventricular preload and
afterload (6-8). In particular, the assessment of isovolumic
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relation in eight of the nine patients, demonstrating a
positive inotropic effect of this agent. The maximal rate
of left ventricular pressure development (peak positive
dP/dt) increased from 1,030 :t 142 to 1,381 :t 219 mm
Hg/s (p < 0.01) on enoximone despite a significant de-
crease in preload (as assessed by left ventricular end-
diastolic pressure and volume) and a small, insignificant
decrease in mean arterial pressure. Two patients devel-
oped angina after enoximone administration; both pa-
tients had coronary artery disease and experienced a
greater than 30% increase in heart rate-systolic blood
pressure product.
Thus, enoximone has a significant inotropic effect in
patients with severe heart failure. Like other inotropic
drugs, it has the potential to increase myocardial oxygen
demand and thereby precipitate ischemia.
(J Am Coli CardioI1987;9:11l7-23)
phase indexes of left ventricular contractile function, such
as the maximal rate of left ventricular pressure development
(peak positive left ventricular dP/dt), has shown an im-
provement in these indexes in most (1,2,9) but not all (6)
studies.
Recently, the end-systolic pressure-volume relation has
emerged as a relatively load-independent measure of left
ventricular contractile function (10-13). Borow et a1. (14)
used the end-systolic pressure-dimension relation derived
from M-mode echocardiography to demonstrate a positive
inotropic effect of milrinone in normal subjects. This tech-
nique cannot be extended to patients with severe heart fail-
ure, however, because most of these subjects have regional
wall motion abnormalities, which preclude the use of M-
mode echocardiography to assess chamber size.
The present study is the first to utilize the left ventricular
end-systolic pressure-volume relation derived from left ven-
tricular pressure-VOlume loops to assess the inotropic effect
0735-1097/87/$3.50
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of a phosphodiesterase inhibitor, enoximone, in patients
with severe heart failure. The study demonstrates that an
increase in contractility contributes to the improved ven-
tricular performance brought about by this agent.
Methods
Study patients. The study group comprised seven men
and two women (mean age 60 ± 3 years) with severe
congestive heart failute. All patients had New York Heart
Association class IV symptoms despite treatment with di-
goxin, diuretics and vasodilators (including captopril in seven
of the nine patients). The mean left ventricular ejection
fraction was 0.22 ± 0.03. Six patients had coronary artery
disease and three (Cases 5, 7 and 8) had idiopathic dilated
cardiomyopathy. Seven patients had sinus rhythm and two
(Cases 2 and 5) had atrial fibrillation. Informed consent was
obtained from all patients.
Protocol. Digoxin, diuretics and vasodilators were dis-
continued 8 to 24 hours before catheterization and no pre-
medication was given. Left heart catheterization was per-
formed from the femoral approach using a micromanometer-
tipped catheter (Millar) in six patients and a fluid-filled
catheter in three patients (Cases I, 2 and 5). Right heart
catheterization was performed with a triple lumen balloon-
tipped thermodilution catheter.
After baseline data were collected, nitroprusside infusion
was begun at 10 to 25 j.tg/min and titrated to achieve a 10
to 15 mm Hg decrease in mean arterial pressure. Data were
collected during the nitroprusside infusion (mean dose
82 ± 7 j.tg/min), and again at least 15 minutes after dis-
continuation of nitroprusside, when arterial pressure had
returned to the baseline value. Enoximone (0.5 mg/kg body
weight) was then infused intravenously over 3 minutes; this
dose was repeated 15 minutes later in all but one patient
(Case 1), who developed angina after the first dose. Mea-
surements were made 10 to 20 minutes after the final en-
oximone dose.
Hemodynamic measurements. The following hemo-
dynamic variables were recorded: heart rate (HR), right
atrial pressure (RAP), pulmonary artery pressure (PAP),
pulmonary capillary wedge pressure (PCWP), left ventric-
ular pressure, mean systemic arterial pressure (MAP) and,
in the patients with micromanometer-tipped catheters, left
ventricular dP/dt (by electronic differentiation). Cardiac out-
put (CO) was obtained by the thermodilution technique.
Calculations of cardiac index (CI), systemic vascular re-
sistance (SVR), pulmonary vascular resistance (PVR), stroke
volume index (SVI) and stroke work index (SWI) were made
using the following formulas: CI = CO/body surface area;
SVR (dynes-s-cm t ') = 80(MAP - RAP)/CO; PVR =
80(PAP - PCWP)/CO; SVI (rnl/rrr') = CIIHR and SWI
(g-rn/m") = (MAP - LV end-diastolic pressure) (0.0136)
(SVI).
Gated blood pool imaging. After in vivo labeling of
patient red blood cells with 20 mCi of technetium-99m,
supine gated blood pool images were acquired in the anterior
and left anterior oblique views; 200,000 counts were col-
lected for the anterior view (16 frames) and 500,000 counts
for the left anterior oblique view (32 frames). The acqui-
sitions were normalized to the frame with the maximal num-
ber of counts and then filtered spatially and temporally. A
time-activity curve of the left ventricle was constructed us-
ing a semiautomated edge detection method with a variable
region of interest. Ejection fraction was calculated as stroke
counts/end-diastolic counts.
Baseline left ventricular end-diastolic volume was de-
rived from the anterior and left anterior oblique views using
a previously validated geometric biplane area-length method
(15, 16). Volumes at other time points in the cardiac cycle
were calculated from the left anterior oblique scan as the
end-diastolic volume multiplied by the ratio of counts in a
particular frame to counts in the end-diastolic frame. During
nitroprusside infusion and after enoximone administration,
images were acquired only in the left anterior oblique view.
Volumes were calculated as the baseline end-diastolic vol-
ume multipled by the ratio of counts in a particular frame
to counts in the baseline end-diastolic frame. Care was taken
to avoid patient and camera movement between treatment
periods. The time-activity curves obtained after the two drug
interventions were corrected for differences from the base-
line in acquisition time and frame interval, and for physical
and biologic decay of the isotope (17).
Pressure-volume loops. Left ventricular pressure read-
ings from 5 to 10 consecutive beats were traced and digitized
on a Summagraphics Bitpad interfaced to a VAX 780 com-
puter. Average pressure was taken at the same frame interval
as the volume images. Pressure-volume loops were then
constructed by plotting these pressures with the correspond-
ing volumes starting at a simultaneous time point (the peak
of the R wave of the electrocardiogram).
Statistics. All results are expressed as mean ± SEM.
For each measurement, overall comparison of the four treat-
ment periods was made by analysis of variance; comparisons
of group means were made using Neuman-Keuls test (18).
Differences were considered significant if the probability
(p) value was < 0.05.
Results
Baseline hemodynamics (Table 1). The baseline heart
rate was 91 ± 4 beats/min and mean arterial pressure was
86 ± 4 mm Hg. Baseline pulmonary capillary wedge pres-
sure and left ventricular end-diastolic pressure were ele-
vated, and cardiac index was depressed. There were no
significant differences between the two control periods in
any of the measured or derived variables.
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Table 1. Effects of Nitroprusside and Enoximone on Hemodynamic Variables
Control I Nitroprusside Control 2 Enoxmione
HR (beats/min) 91 ± 4 99 ± 5* 90 ± 4 104 ± 5§
MAP (mmm Hg) 86 ± 4 73 ± 2t 87 ± 4 84 ± 4#
RAP (mm Hg) 7 ± I 3 ± It 8 ± I 3 ± I§
PAP (mm Hg) 35 ± 5 20 :t 3t 36 ± 4 29 ± 5*-#
PCWP (mm Hg) 23 ± 3 II :t 2t 23 :t 3 17 ± 411
LVEDP (mm Hg) 24 ± 3 13 ± 3t 24 ± 4 18 ± 5U
CI (liters/min per m2) 2.4 ± 0.2 2.8 ± 0.2* 2.4 ± 0.2 3.2 ± 0.2§.11
SVI (ml/m') 28 ± 3 29 ± 3 27 ± 3 32 ± 4
SWI (g-rn/nr') 23 ± 3 24 ± 2 23 ± 3 29 ± 3
SVR (dynes-s-cm 5) 1470 ± 175 1082 ± 86t 1485 ± 163 11 59 ± I77t
PVR (dynes-s-cm 5) 232 ± 55 133 ± 22t 260 ± 53 178 :t 44t
LV Peak + dP/dt 1025 ± 142 1050 ± 144 1030 ± 142 1381 :t 219§ ,#
(mm Hg/s)
LV EF 0.22 ± 0.03 0.25 ± 0.03* 0.24 ± 0.03§
HR x SBP (mm Hg- 10037 ± 778 9206 ± 689 10016 ± 726 11691 :t 985§,#
beats/min)
*p < 0.05, tp < 0.01 nitroprusside versus control I; tp < 0.05. §p < 0.01 enoximone versus control 2;
lip < 0.05, #p < 0.01enoximone versusnitroprusside. Values shownare mean :t SEM. CI = cardiac index;
EF = ejection fraction; HR = heart rate; LV = left ventricular; LVEDP = left ventricular end-diastolic
pressure; MAP = mean arterial pressure; PAP = mean pulmonary arterial pressure; PCWP = pulmonary
capillary wedge pressure: PVR = pulmonary vascular resistance; RAP = right atrial pressure; SBP = systolic
blood pressure; SVI = stroke-volume index; SVR = systemic vascular resistance; SWI = stroke work index .
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Figure 1. Percentage change from control in measured and cal-
culated hemodynamic variables produced by administration of ni-
troprusside or enoximone. CI = cardiac index; dP/dt = maximal
rate of rise in pressure; EF = ejection fraction; HR = heart rate;
LV = left ventricular; LVEDP = left ventricular end-diastolic
pressure; MAP = mean arterial pressure; RAP = right atrial
pressure; SBP = systolic blood pressure; SVR = systemic vas-
cular resistance; SWI = stroke work index.
prusside, although the increase was not statistically signifi-
cant.
Assessment of left ventricular contractile function.
Peak positive left ventricular dP/dt (measured in six patients)
was unchanged with nitroprusside ( I ,025 ± 142 to
1,050 ± 144 mm Hg/s, p = NS), but increased 34% with
enoximone (1 ,030 ± 142 to 1,381 ± 219 mm Hg/s, p <
Hemodynamic responses to nitroprusside and enoxi-
mone (Table 1, Fig. 1). During sodium nitroprusside in-
fusion (82 ± 7 p,g/min ), mean arterial pressure , right atrial
pressure , pulmonary artery and capillary wedge pressures
and systemic and pulmonary vascular resistances all de-
creased, whereas heart rate increased. Left ventricular end-
diastolic pressure decreased from 24 ± 3 to 13 ± 3 mm
Hg (p < 0.0 I) and cardiac index increased .
Enoximone administration (75 ± /5 mg) resulted in no
change in mean arterial pressure, a decrease in systemic
vascular resistance, a decrease in left ventricular end-dia-
stolic pressure from 24 ± 4 to 18 ± 5 mm Hg (p < 0.05)
and an increase in cardiac index . As with nitroprusside,
right atrial pressure, pulmonary artery and capillary wedge
pressures and pulmonary vascular resistance decreased, al-
though the fall in pulmonary capillary wedge pressure was
not statistically significant. Heart rate increased from 90 ±
4 to 104 ± 5 (p < 0.01) after enoximone.
Comparison of the effects o] nitroprusside with those of
enoximone (Fig. 1) shows that , for a similar decrease in
systemic vascular resistance (26% after nitroprusside versus
22% after enoximone , p = NS), enoximone produced a
larger increase in cardiac index (36 versus 15%, p < 0.05).
The higher cardiac index with enoximone was due to both
a higher heart rate and a higher stroke volume index. Left
ventricular end-diastolic pressure decreased to a greater ex-
tent with nitroprusside than with enoximone (p < 0.05).
Left ventricular end-diastolic volume decreased from
245 ± 21 to 221 ± 23 ml with nitroprusside (p < 0.01)
and to 218 ± 25 ml with enoximonc (p < 0.01). Stroke
work index increased more with enoximone than with nitro-
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0.01). This increase in dP/dt occurred despite a lower pre-
load. as assessed by left ventricular end-diastolic pressure
and volume. and a small but insignificant decrease in af-
terload, as estimated from mean arterial pressure. Ejection
fraction increased slightly with both drugs. from 0.22 ±
0.03 in the control period to 0.25 ± 0.03 (p < 0.05) with
nitroprusside and to 0.24 ± 0.03 (p < 0.01) with enoxi-
mone.
Figure 2. Left ventricular pressure-volume loops in the nine pa-
tients shown at baseline (•...•). during nitroprusside infusion
(0-0) and after enoximone administration (X-X). The dashed
lines indicate the hypothetical baseline pressure-volume relations
determined bydrawing a line tangential totheend-systolic portion
of the loops at baseline and during nitroprusside infusion. In all
patients except in Case 2, enoximone shifted the end-systolic por-
tion of the pressure-volume loop upward or leftward, orboth, from
the baseline pressure-volume relation. indicating improved left
ventricular contractile function .
Pressure-volume loops for all nine patients are shown in
Figure 2. It is apparent that in all but one case (Case 2).
the end-systolic pressure-volume point of the enoximone
curve is shifted leftward and upward from a hypothetical
line connecting the end-systolic points of the baseline and
nitroprusside curves. This shift indicates an improvement
in systolic performance which cannot be accounted for solely
by a reduction in afterload, and therefore demonstrates en-
hanced left ventricular contractile function.
Side effects. Two patients (Cases I and 9) experienced
typical angina shortly after receiving enoximone. For the
entire group, the rate-pressureproduct (heart rate multiplied
by systolic blood pressure) decreased slightly with nitro-
prusside. but increased 17% with enoximone because of a
16% increase in heart rate (Table I) . The two patients who
developed angina had coronary artery disease. and they had
the largest increases (>30%) in rate-pressure product (13.224
to 17,424 and 8,850 to 11,808 mm Hg-beats/rnin, respec-
tively). compared with an average increase of 12% (range
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I to 24%) in the other patients. No patient had symptomatic
hypotension or ventricular arrhythmia.
Discussion
Although several studies (3,8,9, 19) have shown that the
acute administration of enoximone brings about hemody-
namic improvement in patients with heart failure. it has
been moredifficultto demonstrate a positive inotropic effect
of the drug in vivo because of its concomitant vasodilator
effect. In this study, we analyzed the left ventricular end-
systolic pressure-volume relation, a relatively load-insen-
sitive index of left ventricular contractile function, to assess
whetherenoximonehas a significant positiveinotropic effect
in patients with heart failure.
Assessment of left ventricular contractile function,
Previous investigations of the inotropic effect of phospho-
diesterase inhibitors includedmeasurements of peak positive
left ventricular dP/dt, which was shown to increase 42, 30
and IS to 23%, respectively, after administration of amri-
none (I ) , milrinone (2,7) and enoximone (9, 19) in patients
with heart failure. We observed a similar 34% increase in
peak positive dP/dt with intravenous enoximone. In con-
trast, Wilmshurst et al. (6) were unable to show any change
in dP/dt in 14patientswithcardiomyopathy given amrinone,
and concluded that the hemodynamic improvement that they
observed was due to vasodilation. Although an increase in
peak positive dP/dt is suggestive of an improvement in con-
tractility, it may also be augmented by increases in heart
rate or left ventricular preloador afterload (20,21). Because
enoximone administration brought about a decrease in left
ventricular preload (as assessed by left ventricular end-di-
astolic pressure and volume), a small but insignificant de-
crease in mean arterial pressure and only a small increase
in heart rate, the observed increase in peak positive dP/dt
most likely reflects an improvement in contractility.
Ejection phase indexes of contractility have also been
measured in patients receiving phosphodiesterase inhibi-
tors . Kereiakes et al. (22) demonstrated a decrease in left
ventricular ejection time corrected for heart rate despite an
increase in stroke volume. However, as they pointed out,
this effect may also have been due to the decrease in arterial
pressure. Bairn et al. (2) reported a 27% increase in rest
left ventricular ejection fraction after 6 months of treatment
with oral milrinone. Borow et al. (14) demonstrated dose-
dependent increases in left ventricular percent fractional
shortening and rate-corrected velocity of fiber shortening
with milrinone in men without heart disease. In the present
study, the acute administration of intravenous enoximone
to patients with heart failure resulted in a small increase in
left ventricular ejection fraction, although it is not known
whether this small increase is of clinical importance.
Recently, Ludmer et al. (23) administered milrinone di-
rectly into the left coronary artery of patients with heart
failure. They showed that an increase in peak positive left
ventricular dP/dt and stroke volume index couldbe achieved
at intracoronary doses that had little systemic effect, indi-
cating a positive inotropic effect of milrinone.
End-systolic pressure-volume analysis. Definitive
demonstration of the positive inotropic effect of the phos-
phodiesterase inhibitors has awaited the utilization of a rel-
atively load-independent measure of left ventricular con-
tractility. Suga et al. (10) showed that the end-systolic
pressure-volume relation of the canine left ventricle is in-
sensitive to changes in preload and that the slope of a line
connecting several end-systolic pressure-volume points is
sensitive to changes in contractility. End-systolic pressure-
volume analysis has subsequently been extended to humans
and has been shown to be a sensitive indicatorof inotropic
state independent of loading conditions (12,13,17,24).
Borow et al. (14) used an approximation of the end-
systolic pressure-dimension relation derived from the di-
crotic notch pressure of the calibrated carotid pulse tracing
and minimal (end-ejection) left ventricular dimension from
M-mode echocardiography to demonstrate a positive ino-
tropic effect of milrinone in normal men. Konstam et al.
(25)employed a similar approximation of the left ventricular
end-systolic pressure-volumerelationderivedfrom systemic
arterial dicrotic notch pressure and minimal (end-ejection)
radionuclide left ventricular volume to suggest that amri-
none had an inotropic effect in some patients with heart
failure. End-ejection volume may differ from true end-sys-
tolic volume, however, particularly in the presenceof mitral
regurgitation (I I). In contrast, Kereiakes et al. (22) were
unable to show a significant increase in the ratio of peak
systolic blood pressure to end-ejection volume index in pa-
tients treated with enoximone. Their inability to document
an inotropic effect may have been due to the failure of peak
systolic blood pressure to adequately correlate with end-
systolic pressure, to the failure of nuclear probe measure-
ments to accurately measure left ventricular volume, par-
ticularly in patients with regionalwall motionabnormalities,
or to differences between end-ejection and end-systolic vol-
umes.
We have employed left ventricular pressure-volume loops
to demonstrate thatenoximoneshifts the leftventricularend-
systolic pressure-volume relation upward and leftwardfrom
the baseline end-systolic pressure-volume relation derived
using the pure vasodilator nitroprusside. We believe that
this is the strongest evidence to date that enoximone exerts
a significant positive inotropic effect in patients with severe
congestive heart failure. .
In comparison with nitroprusside, enoximone produced
a larger increase in cardiac index . despitea similardecrease
in systemic vascular resistance. These findings are similar
to those of other investigations comparingthe hemodynamic
effects of milrinone (7) or enoximone(8) with nitroprusside.
The greater increase in cardiac index with enoximone was
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associated with both a higher heart rate and a greater stroke
volume index.
Side effects. Two patients developed angina several min-
utes after the administration of enoximone. Both patients
had multivessel coronary artery disease and experienced a
> 30% increase in rate-pressure product, compared with an
average increase of 12% for the other seven patients. Packer
et al. (26) reported on four patients who developed wors-
ening manifestations of ischemia, including myocardial in-
farction in three, while receiving oral amrinone. Similarly,
3 of 20 patients treated with oral milrinone experienced more
frequent anginal episodes (2). It is probable that ischemia
occurred because of an increase in myocardial oxygen con-
sumption resulting from the increases in heart rate, arterial
pressure and contractility, which were not counterbalanced
by a fall in wall tension due to a decrease in ventricular
chamber size. Other potential mechanisms for the induction
of ischemia, such as alterations in the distribution of regional
coronary blood flow, were not assessed in this study.
Several investigations of the myocardial energetics of
phosphodiesterase inhibitors have been carried out. Benotti
et al. (27) studied nine patients given intravenous amrinone
and showed a decline in arterial-coronary sinus oxygen dif-
ference, coronary blood flow and myocardial oxygen up-
take. On the other hand, two studies (28,29) have shown
small, but significant, increases in myocardial oxygen con-
sumption in patients given intravenous enoximone. Fur-
thermore, although Monrad et al. (30) reported no increase
in mean rate-pressure product or myocardial oxygen con-
sumption in 18 patients given oral milrinone, more than half
of their patients had an increase in myocardial oxygen con-
sumption, and this increase was>30% in 4 patients. Despite
this increase in oxygen demand, none of the four patients
experienced angina, probably because three of them had
dilated cardiomyopathy without coronary artery disease and
the fourth patient had undergone prior coronary revascu-
larization.
Limitations of the study. The incorporation of left heart
catheterization into the study protocol, while enabling us to
construct pressure-volume loops for the left ventricle, im-
posed time constraints that limited the study in several ways.
First, only two baseline pressure-volume loops were ob-
tained for each patient, and the hypothetical end-systolic
pressure-volume relation was constructed by drawing a line
tangential to the two loops. This method is based on the
assumption that the end-systolic pressure-volume relation is
linear in patients with severe heart failure and can thus be
reliably constructed with data from only two afterload states.
Second, afterload was not varied with nitroprusside during
enoximone administration; hence the full left ventricular
end-systolic pressure-volume relation for enoximone was
not derived. It is clear that, in eight of the nine subjects,
the position of the end-systolic pressure-volume relation on
enoximone is leftward or upward, or both, of the baseline
relation, indicating an improvement in systolic performance
not completely accounted for by a reduction in afterload.
We did not determine, however, whether the slope of the
end-systolic pressure-volume relation is altered by enoxi-
mone.
Also, because of time considerations, nuclear scanning
was not performed during the second control period. There-
fore, the radionuclide scan obtained after enoximone admin-
istration was compared with the scan from the first control
period. However, because there were no differences be-
tween the control periods in any of the hemodynamic vari-
ables, it is unlikely that this resulted in a significant error.
Finally, we did not measure serum levels of enoximone
in this study, and it is possible that the angina that occurred
in two patients was associated with a high serum level. For
this reason, the finding of angina after acute enoximone
administration cannot be extended to chronic oral therapy,
which may be associated with lower drug levels.
Summary and implications for therapy. In patients
with severe heart failure, the acute administration of the
phosphodiesterase inhibitor enoximone brings about an im-
provement in left ventricular contractile function. The ino-
tropic effect of enoximone was demonstrated in this study
by left ventricular end-systolic pressure-volume analysis,
which is relatively insensitive to simultaneous changes in
loading conditions. Angina occurs in some patients after the
acute administration of intravenous enoximone; the rele-
vance of this observation to long-term enoximone treatment
is not known.
We thank Judith Scheer, RN for valuable assistance and William Gross-
man, MD and W. John Powell, MD for thoughtful review of the manu-
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